{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360004232003804672.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1016/j.beha.2018.07.002"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S1521692618300240?httpAccept=text/xml"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S1521692618300240?httpAccept=text/plain"}},{"identifier":{"@type":"PMID","@value":"30213402"}}],"resourceType":"学術雑誌論文(journal article)","dc:title":[{"@value":"Extranodal NK/T-cell lymphoma: Updates in biology and management strategies"}],"description":[{"notation":[{"@value":"Extranodal NK/T-cell lymphoma, nasal type (ENKL), is a rare lymphoma subtype of peripheral T/NK-cell lymphoma that is very common in East Asia and Latin America. Two-thirds of patients have localized disease in the nasal cavity or adjacent sites. Large retrospective studies have revealed the clinicopathologic features of ENKL patients, identified risk factors for short survival time, and developed prognostic models. Next-generation sequencing studies have provided a comprehensive list of recurrent mutations in ENKL. Since the early 2000s, disease-specific therapeutic approaches have been developed, and the standard of care for ENKL has markedly changed. Non-anthracycline-containing chemotherapy with or without radiotherapy is the current standard approach for ENKL treatment. Emerging therapies, including the use of immune checkpoint inhibitors, are being investigated."}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1420564276174963200","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"50359767"},{"@type":"NRID","@value":"1000050359767"},{"@type":"NRID","@value":"9000301717270"},{"@type":"NRID","@value":"9000258044030"},{"@type":"NRID","@value":"9000002474666"},{"@type":"NRID","@value":"9000021510634"},{"@type":"NRID","@value":"9000240538417"},{"@type":"NRID","@value":"9000258044505"},{"@type":"NRID","@value":"9000258044219"},{"@type":"NRID","@value":"9000258044725"},{"@type":"NRID","@value":"9000411826788"},{"@type":"NRID","@value":"9000396109508"},{"@type":"NRID","@value":"9000258041809"},{"@type":"NRID","@value":"9000414077274"},{"@type":"NRID","@value":"9000378112092"},{"@type":"NRID","@value":"9000258045390"},{"@type":"NRID","@value":"9000018839975"},{"@type":"NRID","@value":"9000396109121"},{"@type":"NRID","@value":"9000258046080"},{"@type":"NRID","@value":"9000258045925"},{"@type":"NRID","@value":"9000362196752"},{"@type":"NRID","@value":"9000238231960"},{"@type":"NRID","@value":"9000258043862"},{"@type":"NRID","@value":"9000002150251"},{"@type":"NRID","@value":"9000383709219"},{"@type":"NRID","@value":"9000258042316"},{"@type":"NRID","@value":"9000258044206"},{"@type":"NRID","@value":"9000241580456"},{"@type":"NRID","@value":"9000002055788"},{"@type":"NRID","@value":"9000258042693"},{"@type":"NRID","@value":"9000413550859"},{"@type":"NRID","@value":"9000001133939"},{"@type":"NRID","@value":"9000248214727"},{"@type":"NRID","@value":"9000402436286"},{"@type":"NRID","@value":"9000258042223"},{"@type":"NRID","@value":"9000001138455"},{"@type":"NRID","@value":"9000412264792"},{"@type":"NRID","@value":"9000378112174"},{"@type":"NRID","@value":"9000303991421"},{"@type":"NRID","@value":"9000021327338"},{"@type":"NRID","@value":"9000283540305"},{"@type":"NRID","@value":"9000326647777"},{"@type":"NRID","@value":"9000021568482"},{"@type":"NRID","@value":"9000002403571"},{"@type":"NRID","@value":"9000410284590"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/myamaguchi1"}],"foaf:name":[{"@value":"Motoko Yamaguchi"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004232003804801","@type":"Researcher","foaf:name":[{"@value":"Masahiko Oguchi"}]},{"@id":"https://cir.nii.ac.jp/crid/1420564276171485184","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"20280810"},{"@type":"NRID","@value":"1000020280810"},{"@type":"ORCID","@value":"0000-0002-5974-7614"},{"@type":"NRID","@value":"9000001952657"},{"@type":"NRID","@value":"9000263062273"},{"@type":"NRID","@value":"9000412602513"},{"@type":"NRID","@value":"9000307251415"},{"@type":"NRID","@value":"9000319550653"},{"@type":"NRID","@value":"9000000569069"},{"@type":"NRID","@value":"9000014155554"},{"@type":"NRID","@value":"9000283454071"},{"@type":"NRID","@value":"9000345435185"},{"@type":"NRID","@value":"9000409880769"},{"@type":"NRID","@value":"9000258037246"},{"@type":"NRID","@value":"9000018531395"},{"@type":"NRID","@value":"9000345249871"},{"@type":"NRID","@value":"9000258043639"},{"@type":"NRID","@value":"9000258042959"},{"@type":"NRID","@value":"9000263056610"},{"@type":"NRID","@value":"9000413692609"},{"@type":"NRID","@value":"9000413774044"},{"@type":"NRID","@value":"9000410507933"},{"@type":"NRID","@value":"9000403322393"},{"@type":"NRID","@value":"9000242258684"},{"@type":"NRID","@value":"9000014160465"},{"@type":"NRID","@value":"9000261668268"},{"@type":"NRID","@value":"9000283540329"},{"@type":"NRID","@value":"9000018839899"},{"@type":"NRID","@value":"9000020411553"},{"@type":"NRID","@value":"9000258038404"},{"@type":"NRID","@value":"9000326666946"},{"@type":"NRID","@value":"9000021855642"},{"@type":"NRID","@value":"9000016393017"},{"@type":"NRID","@value":"9000315680803"},{"@type":"NRID","@value":"9000258037352"},{"@type":"NRID","@value":"9000242720997"},{"@type":"NRID","@value":"9000412637791"},{"@type":"NRID","@value":"9000310002250"},{"@type":"NRID","@value":"9000392783576"},{"@type":"NRID","@value":"9000248227049"},{"@type":"NRID","@value":"9000263062287"},{"@type":"NRID","@value":"9000412109361"},{"@type":"NRID","@value":"9000326647557"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/read0166236"}],"foaf:name":[{"@value":"Ritsuro Suzuki"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"15216926"}],"prism:publicationName":[{"@value":"Best Practice & Research Clinical Haematology"}],"dc:publisher":[{"@value":"Elsevier BV"}],"prism:publicationDate":"2018-09","prism:volume":"31","prism:number":"3","prism:startingPage":"315","prism:endingPage":"321"},"reviewed":"false","dc:rights":["https://www.elsevier.com/tdm/userlicense/1.0/"],"url":[{"@id":"https://api.elsevier.com/content/article/PII:S1521692618300240?httpAccept=text/xml"},{"@id":"https://api.elsevier.com/content/article/PII:S1521692618300240?httpAccept=text/plain"}],"createdAt":"2018-07-03","modifiedAt":"2020-11-04","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Lymphoma,%20Extranodal%20NK-T-Cell","dc:title":"Lymphoma, Extranodal NK-T-Cell"},{"@id":"https://cir.nii.ac.jp/all?q=Antineoplastic%20Combined%20Chemotherapy%20Protocols","dc:title":"Antineoplastic Combined Chemotherapy Protocols"},{"@id":"https://cir.nii.ac.jp/all?q=High-Throughput%20Nucleotide%20Sequencing","dc:title":"High-Throughput Nucleotide Sequencing"},{"@id":"https://cir.nii.ac.jp/all?q=Humans","dc:title":"Humans"},{"@id":"https://cir.nii.ac.jp/all?q=Chemoradiotherapy","dc:title":"Chemoradiotherapy"},{"@id":"https://cir.nii.ac.jp/all?q=Disease-Free%20Survival","dc:title":"Disease-Free Survival"}],"project":[{"@id":"https://cir.nii.ac.jp/crid/1040000781968770944","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"17K09924"},{"@type":"JGN","@value":"JP17K09924"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-17K09924/"}],"notation":[{"@language":"ja","@value":"東アジア共同によるNK/T細胞リンパ腫新世代治療の最適化"},{"@language":"en","@value":"Optimization of new generation therapy for NK/T-cell lymphoma in East Asia"}]}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360002214550200832","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Frequent <i>BCOR</i> aberrations in extranodal <scp>NK/T</scp>‐Cell lymphoma, nasal type"}]},{"@id":"https://cir.nii.ac.jp/crid/1360002218954832384","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses"}]},{"@id":"https://cir.nii.ac.jp/crid/1360002219027213440","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004236879471872","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: An Updated Analysis of the Japan Clinical Oncology Group Study JCOG0211"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011145214728192","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project"}]},{"@id":"https://cir.nii.ac.jp/crid/1360283690797993472","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation"}]},{"@id":"https://cir.nii.ac.jp/crid/1360283695486348544","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Rare occurrence of<i>JAK3</i>mutations in natural killer cell neoplasms in Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285705108131200","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Frequent expression of <scp>CD</scp>30 in extranodal <scp>NK</scp>/<scp>T</scp>‐cell lymphoma: Potential therapeutic target for anti‐<scp>CD</scp>30 antibody‐based therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285710466771328","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Early disease progression in patients with localized natural killer/T‐cell lymphoma treated with concurrent chemoradiotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285711737588096","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292619544247680","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292620913006592","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292621221486336","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Complete remission in CD30-positive refractory extranodal NK/T-cell lymphoma with brentuximab vedotin"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292621338292864","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Activated <scp>J</scp>anus <scp>K</scp>inase 3 expression not by activating mutations identified in <scp>N</scp>atural <scp>K</scp>iller/<scp>T</scp>‐cell lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574094186034816","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"L-Asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574094688254848","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Phase I/II Study of Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: Japan Clinical Oncology Group Study JCOG0211"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574094816596608","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574095821292160","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Extranodal natural killer/T-cell lymphoma from skin or soft tissue: suggestion of treatment from multinational retrospective analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574096516879360","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Comparative genomic hybridization study of nasal‐type NK/T‐cell lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846640217549056","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846643959679232","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Treatments and Outcomes of Patients With Extranodal Natural Killer/T-Cell Lymphoma Diagnosed Between 2000 and 2013: A Cooperative Study in Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855569018384256","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855569931824256","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855570213630336","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"High-dose therapy and autologous stem cell transplantation for extra-nodal NK/T lymphoma in patients from the Western hemisphere: a study from the European Society for Blood and Marrow Transplantation"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855570234736640","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Targeting CD38 in Refractory Extranodal Natural Killer Cell–T-Cell Lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855570329466880","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"P53, N- and K-Ras, and β-catenin gene mutations and prognostic factors in nasal NK/T-cell lymphoma from Hokkaido, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137044198859776","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137044245720320","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Immunotherapy of Lymphoma and Myeloma: Facts and Hopes"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137044790081408","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The impact of the omission or inadequate dosing of radiotherapy in extranodal natural killer T‐cell lymphoma, nasal type, in the United States"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137045251621632","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Molecular underpinning of extranodal NK/T-cell lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418518481973888","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418519052147968","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"PD1 blockade with low-dose nivolumab in NK/T cell lymphoma failing l-asparaginase: efficacy and safety"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418519321296384","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418520401352704","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Modern Radiation Therapy for Extranodal Lymphomas: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418520715605760","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Identification of del(6)(q21q25) as a recurring chromosomal abnormality in putative NK cell lymphoma/leukaemia"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418521028148096","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699993449686528","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699993645243520","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"CXC Chemokine Receptor 3 and CC Chemokine Receptor 4 Expression in T-Cell and NK-Cell Lymphomas with Special Reference to Clinicopathological Significance for Peripheral T-Cell Lymphoma, Unspecified"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699994515844608","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699996090344448","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"GDP (Gemcitabine, Dexamethasone, and Cisplatin) Is Highly Effective and Well-Tolerated for Newly Diagnosed Stage IV and Relapsed/Refractory Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699996133378944","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"CD3−CD56+ Non-Hodgkin's Lymphomas With an Aggressive Behavior Related to Multidrug Resistance"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981470064824576","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981470399997568","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"P-Glycoprotein Expression on Normal and Abnormally Expanded Natural Killer Cells and Inhibition of P-Glycoprotein Function by Cyclosporin A and Its Analogue, PSC833"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981470504863232","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Allogeneic haematopoietic SCT for natural killer/T-cell lymphoma: a multicentre analysis from the Asia Lymphoma Study Group"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262943770630784","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262944034232448","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262944864158720","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Long-term Outcome of Extranodal NK/T Cell Lymphoma Patients Treated With Postremission Therapy Using EBV LMP1 and LMP2a-specific CTLs"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262946341740928","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544419677974144","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Phase II Trial of Concurrent Radiation and Weekly Cisplatin Followed by VIPD Chemotherapy in Newly Diagnosed, Stage IE to IIE, Nasal, Extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825894759952256","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The diagnosis and management of NK/T-cell lymphomas"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825895572758272","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Genome‐wide array‐based comparative genomic hybridization of natural killer cell lymphoma/leukemia: Different genomic alteration patterns of aggressive NK‐cell leukemia and extranodal Nk/T‐cell lymphoma, nasal type"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825896407023744","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Extranodal Natural Killer T-Cell Lymphoma, Nasal-Type: A Prognostic Model From a Retrospective Multicenter Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107369028907264","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Comparative Genomic Hybridization Analysis of Natural Killer Cell Lymphoma/Leukemia"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107369231241600","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107369440083712","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Receptor-type tyrosine-protein phosphatase κ directly targets STAT3 activation for tumor suppression in nasal NK/T-cell lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107370562596480","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Concurrent chemoradiotherapy followed by l-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388844086631296","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Frequent mutations of Fas gene in nasal NK/T cell lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388844389595264","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388844751397760","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Radiotherapy As Primary Treatment for Stage IE and IIE Nasal Natural Killer/T-Cell Lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388845047534976","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388845067426304","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388845497527936","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388845834965504","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670320140316672","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670320566931200","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670320892321024","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Phase I study of dexamethasone, methotrexate, ifosfamide, <scp>l</scp>‐asparaginase, and etoposide (SMILE) chemotherapy for advanced‐stage, relapsed or refractory extranodal natural killer (NK)/T‐cell lymphoma and leukemia"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670320969948928","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"<i>PRDM1</i>\n            is a tumor suppressor gene in natural killer cell malignancies"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951795201900288","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951795216582144","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951795284236032","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Recurrent ECSIT mutation encoding V140A triggers hyperinflammation and promotes hemophagocytic syndrome in extranodal NK/T cell lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951795331618048","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951795417855488","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"NK/T Cell Lymphoma: Updates in Therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951795434171776","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951795726484224","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"CD38 expression predicts poor prognosis and might be a potential therapy target in extranodal NK/T cell lymphoma, nasal type"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951795846656384","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233268209912832","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233268225689088","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233269373830912","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Clinical significance of cyclooxygenase-2 expression in extranodal natural killer (NK)/T-cell lymphoma, nasal type"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233269761135488","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Extranodal NK/T‐Cell Lymphoma: Toward the Identification of Clinical Molecular Targets"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233270223301120","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1370568466626923781","@type":"Product","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1370568466626923789","@type":"Product","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Emerging insights on the pathogenesis and treatment of extranodal NK/T cell lymphomas (ENKTL)"}]},{"@id":"https://cir.nii.ac.jp/crid/1370568466626924032","@type":"Product","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"5-year follow-up of the SMILE phase II study for newly-diagnozed stage IV, relapsed or refractory extranodal NK/T-cell lymphoma, nasal type"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679681321728","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Current treatment approaches for NK/T-cell lymphoma"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1016/j.beha.2018.07.002"},{"@type":"KAKEN","@value":"PRODUCT-22068184"},{"@type":"OPENAIRE","@value":"doi_dedup___::c22aef9a077c2fd682b238aa79dba9a9"}]}